Navigation Links
Burrill & Company Responds to Recent Press Coverage About Biopark Investment at Elk Run
Date:9/16/2010

SAN FRANCISCO, Sept. 16 /PRNewswire/ -- In response to recent press coverage concerning investment to support the development of a biobusiness park in Minnesota, Burrill & Company would like to clarify that investment discussions are still ongoing.

"We have been in active discussions for several months with one potential investor who has an interest in the project," said G. Steven Burrill, CEO, Burrill & Company. "However, contrary to the impressions conveyed in the press coverage, no decisions have yet been made and there can be no guarantees about the actual outcome at this point.

"We do have a strong interest in the State of Minnesota and independent of our continuing efforts at Elk Run, we have been actively investing in the State, creating jobs and establishing an innovative biotech venture capital community," Burrill added. "We have already established an office in Minnesota and are actively investing in promising start-up companies. Bringing more than $100 million into the State in the last year is evidence of our significant ongoing commitment to Minnesota, independent of the potential fund commitment."

Burrill & Company investments in Minnesota:

- Invested $8M in Nora Therapeutics, developer of women's reproductive health drugs and devices. Burrill's investment also brought an additional $17M into the company, as part of a syndicate with Prospect Venture Partners and Vivo Ventures.

- In 2009, Burrill & Company invested $5M in Segetis, a start-up company developing chemicals made from biomass. The total investment into the company was over $17M, with additional syndicate member Khosla Ventures. Segetis is located in Golden Valley, MN.

- This year, one of Burrill & Company's portfolio companies, GEVO, acquired a corn-based ethanol plant owned and operated by Agri-Energy in Luverne, MN. The transaction, worth over $20M, will bring the latest isobutanol technology into the State as well as generate dozens of new jobs.

About Burrill & Company

Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. Burrill is also the creator, sponsor and facilitator of leading industry conferences worldwide and publisher of a range of bio-intelligence reports including the monthly Burrill Report (www.burrillreport.com) and annual "State of the Industry" report, the latest of which has just been released entitled Biotech 2010-Life Sciences: Adapting for Success.


'/>"/>
SOURCE Burrill & Company
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shawn Cross Joins Burrill Merchant Banking
2. Burrill & Company Invests in Taiwan Liposome Company
3. Joao Paulo Baptista Joins Burrill & Company
4. CEO of Burrill & Company to Speak at BioConference Live Slated for November 17th and 18th
5. Burrill & Company and WR Hambrecht + Co to Collaborate on OpenIPO(R) Transactions
6. Shawn Cross Appointed CEO of Burrill Merchant Banking Group
7. CardioWest™ Artificial Heart Approved For Highest Reimbursement in CMS History : Plus Up To $53,000 New Technology Add-on Payments
8. 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis
9. Bruker Introduces HyperQuant™, a Unique Bench-Top NMR Reader to Quantify Hyperpolarization
10. Biotechnology & Drug Discovery Markets Push Up Demand for Lab Automation Products, According to a New Report by Global Industry Analysts
11. Human Trial Results Show Plant Extract Tops Drug at Regulating Blood Sugar Levels; Huge Market Seen for Newly Developed Food Additive Emulin™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/25/2017)... , ... February 25, 2017 , ... ... Verified Clinical Trials in an ongoing effort to create meaningful change by ... and pharmaceutical research with emphasis on consumers and patients’ mental health well-being. , ...
(Date:2/24/2017)... , Feb. 24, 2017  Aethlon Medical, Inc. ... note authored by its Chairman and CEO, Jim ... the Munich Security Conference last Saturday, Bill Gates ... could kill more people than nuclear weapons. Mr. Gates ... and U.K. intelligence agencies, that scientific terrorists have access ...
(Date:2/24/2017)... BEIJING, Feb. 23, 2017 China Biologic Products, Inc. ... integrated plasma-based biopharmaceutical company in China, today announced its financial ... Fourth Quarter 2016 Financial Highlights ... increased by 21.7% in RMB terms, or increased by 13.6% ... the same quarter of 2015. Gross profit ...
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook Labs is ... include an array of biochemical analyses critical for Lead Discovery. The company’s ... and SAR programs, including inhibitor potency and selectivity, mechanism of action, and inhibitor ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 7, 2017 The ... largely by the confluence of organizations, desires to ... for knowledge-based systems (password and challenge questions), biometrics ... and government systems. The market is driven by ... demarcation between consumer and enterprise uses cases, with ...
(Date:2/7/2017)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the latest release of ... and award winning eClinical solution, is now available for ... a proven Software-as-a-Service (SaaS) clinical research technology platform that ... delivers an entire suite of eClinical tools to support ...
(Date:2/7/2017)... BEACH, New York , February 7, 2017 /PRNewswire/ ... known as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" ... identity management and electronic transaction processing services, is pleased ... reorganization of the Company. Effective January 31, ... of the Board of Directors, CEO and President.  An ...
Breaking Biology News(10 mins):